chromium-hdl-c

この研究の注釈：

A meta-analysis on chromium in type II diabetics where supplementation lasted for over three months noted that, relative to placebo, there was a mild but significant reduction in blood glucose. HbA1c and all biomarkers of lipid metabolism, as well as weight, were all unaffected.

This meta-analysis was restricted to type II diabetics and the duration of at least three months, but at times included studies containing chromium enriched yeast and biotin supplementation alongside the chromium.

この研究の注釈：

400mcg chromium given to overweight children who were also given exercise and diet plans (relative to diet and exercise paired with placebo) over the course of six weeks failed to reduce bodyweight relative to placebo (at the P level of 0.05) but the reduction in fat mass and increase in lean mass was greater with chromium than with placebo.

Insulin sensitivity was improved to a statistically significant degree, but no other health variable was beneficially influenced.

この研究の注釈：

In obese type II diabetic subjects given trivalent chromium supplementation via Brewer’s Yeast (500mcg chromium) for eight weeks, supplementation was able to exert a minor hypoglycemic effect which failed to reach statistical significance (P=0.08) while trends on other biochemical parameters failed to reach statistical significance.

この研究の注釈：

4 months supplementation of 200mcg or 1,000mcg chromium (as picolinate) in type II diabetics was able to reduce fasting and postprandial blood glucose (higher dose only), fasting and postprandial insulin (both groups equally), HbA1c (higher dose only), and total cholesterol (higher dose only) with no influence on HDL nor body weight.

研究の資金源に関する問題点：

Supported by Nutrition 21, producer of chromium supplements

この研究の注釈：

Supplementation of chromium to type II diabetics for 28 weeks noted a reduction in blood glucose relative to baseline and placebo, and the minor changes in HbA1c and insulin turned out to be significant due to an increase seen in placebo. Weight and blood pressure were not significantly different, nor were any parameter of lipid metabolism measured.

この研究の注釈：

Six months supplementation of chromium at 400mcg via enriched yeast to type II diabetics already on medications failed to confer any additional benefits, particularly the primary outcome (to see if a 0.5% reduction in HbA1c was reached).

この研究の注釈：

Supplementation of 500-1,000mcg chromium (as picolinate) daily for six months in persons with type II diabetes on insulin therapy (but still poorly controlled) failed to find benefits with supplementation relative to placebo.

この研究の注釈：

In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium.

Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.

この研究の注釈：

Low dose chromium supplementation (23.3mcg) via Brewer’s Yeast and 200mcg chromium as trichloride for eight weeks in type II diabetics both appeared to reduce both fasting and postprandial blood glucose (75g glucose tolerance test) and was able to reduce fructosamine as well.

この研究の注釈：

Supplementation of 400mcg chromium (as nicotinate) daily for 16 weeks in persons with HIV who were insulin resistant due to antiretroviral therapy appeared to improve insulin sensitivity and some other measured parameters such as triglycerides and weight when used as adjuvant.

この研究の注釈：

Supplementation of brewers yeast (conferring 42 μg chromium) in newly diagnosed diabetics for three months was able to significantly reduce blood glucose (47.6%), HbA1c (from 9.5% to 6.8%), and systolic blood pressure (12%) while causing some benefit to all lipid parameters except vLDL and HDL relative to placebo.

この研究の注釈：

Supplementation of 1mg chromium as picolinate in obese adults over the course of 24 weeks failed to influence body weight either alone or in combination with nutritional education (teaching participants to eat better) and no other parameter in the blood or via CT scans was modified with supplementation.

この研究の注釈：

Supplementation of chromium picolinate at 500mcg or 1,000mcg for six months in persons at risk for type II diabetes has failed to influence any biomarkers of glucose metabolism and was said to not confer any protection against the development of type II diabetes.

この研究の注釈：

The addition of 200mcg chromium (as chloride) to milk powder, relative to a milk powder placebo, in type II diabetics already on medication (gliclazide) noted that there was a reduction in blood glucose, insulin, and improvement in insulin sensitivity over the course of 16 weeks in men only.

Acute insulin response following an oral glucose tolerance test (10 minutes after) was unaffected in both sexes.

この研究の注釈：

Chromium supplementation at 1,000mcg daily (as picolinate) increased the acute insulin response to glucose but failed to influence any other measured parameter of metabolic syndrome after 16 weeks supplementation in adults with signs of metabolic syndrome yet no diagnosed diabetes.

この研究の注釈：

In 11 middle aged obese women given 400mcg chromium (as picolinate) daily for eight weeks, there was no observable change in the anti-HMdU antibody suggesting no DNA damage from supplementation.

この研究の注釈：

64 women with polycystic ovarian syndrome were randomized to receive 200 µg chromium picolinate or placebo for 8 weeks, and measures of insulin sensitivity and blood lipids were measured. Insulin sensitivity improved, and blood lipid profile trended toward significance.